Welcome to the e-CCO Library!

P330 Inflammatory Bowel Disease (IBD) patients frequently report adverse drug reactions during biologic therapy: A multicentre, prospective, patient-reported pharmacovigilance monitoring system
Year: 2020
Source:

ECCO'20 Vienna

Authors:

P. THOMAS1, R. West2, M. Russel3, J. Jansen4, J. van Lint5, N. Jessurun5, T. Römkens6, F. Hoentjen1

Created: Thursday, 30 January 2020, 10:12 AM
P330: A national survey on therapeutic education in inflammatory bowel disease by an association of caregivers and expert patients: French Association for Therapeutic Education in inflammatory bowel disease (AFEMI)
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. Moreau1, E. Balez2, C. Devos3, X. Hébuterne4, M. Veltin5, M. Allez*6

Created: Friday, 22 February 2019, 9:41 AM
P330: A prospective trial to evaluate the feasibility of a mobile app in patients with inflammatory bowel disease under maintenance therapy
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Coenen1*, E. Weyts1, P. Geens1, E. Nijns2, R. Van Durm2, M. Ferrante1, S. Vermeire1, B. Van den Bosch2, G. Van Assche1

Created: Thursday, 21 February 2019, 9:14 AM
P330: Discontinuation of corticosteroids among ulcerative colitis patients treated with vedolizumab in the United States
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Patel H.*1, Chastek B.2, Null K.D.3, Demuth D.4

Created: Wednesday, 20 February 2019, 10:36 AM
P330: Immunity in patients with inflammatory bowel disease on biologic therapy after COVID 19 vaccination
Year: 2022
Source: ECCO'22
Authors: Knezevic, T.(1);Cujic, D.(2);Odanovic, O.(1);Kralj, D.(1);Gnjatovic, M.(2);Kalaba, A.(1);Vrinic Kalem, D.(1);Svorcan, P.(1,3);Markovic, S.(1,3);
Created: Friday, 11 February 2022, 3:52 PM
P330: Long-term outcomes following a switch from originator adalimumab to the biosimilar SB5 (Imraldi) in IBD
Year: 2021
Source: ECCO'21 Virtual
Authors: Derikx, L.(1,2);Dolby, H.(2);Plevris, N.(2);Lucaciu , L.(2);Rees, C.(2);Lyons, M.(2);Siakavellas, S.(2);Constantine-Cooke, N.(3);Noble, C.(2);O’Hare, C.(2);Merchant, L.(2);Arnott, I.(2);Jones, G.R.(2,4);Lees, C.(2,5);
Created: Wednesday, 2 June 2021, 4:12 PM
P330: Ultrasound remission after biologic induction predicts long-term endoscopic remission in Crohn's disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Allocca, M.(1)*;Dell'Avalle , C.(2);Furfaro, F.(3);Zilli, A.(3);Radice, S.(3);D'Amico, F.(3);Peyrin-Biroulet, L.(4);Fiorino, G.(3);Danese, S.(3);
Created: Friday, 14 July 2023, 11:05 AM
P330: Vitamin D insufficiency in patients with inflammatory bowel disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. d. C. Martos Plasencia*, C. Verdejo Gil, R. H. Lorente Poyatos, E. De la Santa Belda, M. Peña Gómez, R. Salmoral Luque, B. López Viedma, J. Olmedo Camacho

Created: Friday, 22 February 2019, 9:49 AM
P331 Productivity loss in patients with inflammatory bowel disease receiving treatment for iron deficiency anaemia: A comparison of ferric maltol and IV iron
Year: 2020
Source: ECCO'20 Vienna
Authors: S. Howaldt1, I. Jacob2, M. Sampson3, F. Akriche4
Created: Thursday, 30 January 2020, 10:12 AM
Last Modified: Wednesday, 3 March 2021, 4:12 PM by Dauren Ramankulov

Corrigendum:

In the originally published version of this poster presentation, the below corrections have been made.

Upon the original publication, the Results section indicated that the primary non-inferiority endpoint was met. This should have read: “The primary non-inferiority endpoint was not met."

P331: Allopurinol and azathioprine co-therapy or thioguanine dose splitting: shifting the shunters in the mercaptopurine pathway in a paediatric inflammatory bowel disease population—a single-centre experience
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

S. Chadokufa*1, A. Lozinsky Rolnik2, S. Sider1, N. Acton3, B. Huggett3, N. Shah4, F. Kiparissi1

Created: Friday, 22 February 2019, 9:49 AM
P331: Composite outcomes in Crohn’s disease: a systematic review and meta-analysis of observational studies
Year: 2022
Source: ECCO'22
Authors: Estevinho, M.M.(1);Sottomayor, C.(2);Alves, C.(3);Santago, M.(4);Ministro, P.(5);Lago, P.(6);Correia, L.(7);Gonçalves, R.(8);Carvalho, D.(9);Portela, F.(10);Dias, C.C.(11);Dignass, A.(12);Danese, S.(13);Peyrin-Biroulet, L.(14);Magro, F.(15);
Created: Friday, 11 February 2022, 3:52 PM
P331: Development of a novel transabdominal ultrasound disease activity score in patients with ulcerative colitis (UCUS score)
Year: 2018
Source: ECCO '18 Vienna
Authors:

Y. Hashimoto1*, N. Kume1, K. Sato1, T. Kanemura1, A. Haga1, Y. Ishii1, M. Nishio1, H. Otake1, N. Takahashi1, T. Ogashiwa1, M. Izumi2, A. Hanzawa2, H. Yonezawa2, Y. Saigusa3, S. Maeda4, H. Kimura1, R. Kunisaki1

Created: Thursday, 21 February 2019, 9:14 AM
P331: Final results on efficacy and safety of biosimilar infliximab after one-year: results from a prospective nationwide cohort
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Gecse K.B.*1, Vegh Z.1, Kurti Z.1, Rutka M.2, Farkas K.2, Golovics P.A.1, Lovasz B.D.1, Gonczi L.1, Banai J.3, Bene L.4, Gasztonyi B.5, Kristof T.6, Lakatos L.7, Miheller P.8, Nagy F.2, Palatka K.9, Papp M.9, Patai A.10, Salamon A.11, Szamosi T.3, Szepes Z.2, Toth G.T.12, Vincze A.13, Molnar T.2, Lakatos P.L.1

Created: Wednesday, 20 February 2019, 10:36 AM
P331: Real-world assessment of biological treatment of inflammatory bowel disease at an Austrian Referral Centre: the ULTIMATE study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

H. P. Gröchenig*1, E. Walter2, A. Redl3, M. Bresztowanszky1, K. Steidl1, F. Siebert1, G. Novacek5

Created: Friday, 22 February 2019, 9:41 AM
P331: Risk Factors and Prediction Model for Fecal Incontinence in Patients with Crohn's Disease: A Multicenter Study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Wang, C.(1)*;Yang, F.(2);Qiao, L.(1);Chen, Q.(1);Chen, H.(1);Li, Y.(3);Zhang, X.(4);Liao, X.(5);Cao, L.(3,6);Xu, H.(1);Xiang, Y.(1);Wang, X.(7);Yang, B.(1);
Created: Friday, 14 July 2023, 11:05 AM
P331: The safety of tioguanine exposure during pregnancy: a case series of seventy-three pregnancies
Year: 2021
Source: ECCO'21 Virtual
Authors: Crouwel, F.(1);Simsek, M.(1);De Boer, M.A.(2);Mulder, C.J.J.(1);Buiter, H.J.C.(3);De Boer, N.K.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P332 Mindfulness-based stress reduction and cognitive intervention improve the health-related quality-of-life and ability to work in Crohn’s disease patients: A randomised controlled trial
Year: 2020
Source:

ECCO'20 Vienna

Authors:

D. Schwartz1, R. Sergienko2, G. Goren3, S. Reggev3, M. Friger2, A. Nemirovsky4, A. Monsonego4, D. Greenberg5, O. Sarid3, V. Slonim-Nevo3, S. Odes6, Israeli IBD NUcleua IIRN

Created: Thursday, 30 January 2020, 10:12 AM
P332: A treat-to target strategy guided by pan-enteric valuation in paediatric Crohn’s disease improves outcomes at 2 years
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Oliva1*, S. Cohen2, M. Aloi1, S. Mallardo1, F. Viola1, G. D'Arcangelo1, F. Maccioni3, C. Hassan4, P. Papoff5, S. Cucchiara1

Created: Thursday, 21 February 2019, 9:14 AM
P332: External validation of intestinal ultrasound scores to detect endoscopic activity in children and adults with Crohn's disease: A prospective cohort study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Aronskyy, I.(1);Spencer, E.(1);Kellar, A.(1);Pittman, N.(1);Dubinsky, M.(1);Dolinger, M.(1)*;
Created: Friday, 14 July 2023, 11:05 AM
P332: Group-based Acceptance and Commitment Therapy (ACT) is acceptable and effective at reducing psychological distress in patients with Inflammatory Bowel Disease (IBD).
Year: 2022
Source: ECCO'22
Authors: Duff, A.(1);De Petrillo, A.(2);Reynolds, D.(3);Bangura, E.(4);Pavilidis, P.(1);Mawdsley, J.(1);
Created: Friday, 11 February 2022, 3:52 PM